SRTS

Sensus Healthcare, Inc. (SRTS) 10Y Growth Potential Analysis (2026)

Invetso Score: 4.3/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 4.8 (Moderate)

Revenue growth capacity is not evidenced by available five-year CAGR data, so SRTS appears less proven than peer companies with documented multi-year compounding.

R&D intensity at 36.6% of revenue can support product development, but negative ROIC suggests peer-leading reinvestment has not yet translated into scalable revenue expansion.

Low capex at 0.9% of revenue preserves flexibility, yet the absence of demonstrated growth conversion limits confidence versus peers with stronger operating leverage.

The current revenue base can still expand, but the lack of historical growth metrics keeps long-term compounding potential below peers with established execution records.

Market Tailwinds

Score:

No direct evidence of durable end-market acceleration is provided, leaving SRTS with weaker visible tailwinds than peers operating in clearly expanding categories.

The company’s growth outlook depends more on internal execution than on proven external demand support, which reduces relative visibility versus faster-scaling peers.

High R&D spend may align with product refresh cycles, but without market-share or demand data it does not establish stronger tailwinds than peers.

Compared with peers showing documented multi-year demand expansion, SRTS has limited disclosed evidence of structural market support for sustained revenue compounding.

Scalability Expansion

Score:

Capex intensity is low, which can aid scalability, but negative ROIC indicates incremental investment has not yet produced efficient revenue expansion versus peers.

A 536-day cash conversion cycle signals working-capital drag, limiting the speed at which sales growth can be converted into scalable cash generation.

Net debt to EBITDA of 1.56x is manageable, yet weak interest coverage constrains reinvestment flexibility relative to stronger peer balance sheets.

Scalability remains viable, but current efficiency metrics show SRTS is less capable of compounding revenue at scale than higher-conversion peers.

Constraints Limitations

Score:

Negative ROIC is the clearest structural constraint, because it implies reinvested capital has not been generating durable value or scalable revenue growth.

The extremely long cash conversion cycle ties up capital in operations, which limits reinvestment speed and weakens long-term compounding versus peers.

Interest coverage of zero suggests financial fragility, reducing flexibility to fund growth initiatives and making scaling more constrained than for healthier peers.

Missing historical growth disclosure adds uncertainty, but the stronger limitation is that current economics have not yet demonstrated repeatable expansion capacity.

Overall Score

Score:

SRTS shows some reinvestment and balance-sheet capacity, but negative ROIC, weak cash conversion, and limited disclosed growth history keep long-term scaling potential below stronger peers.

Score Driver: Negative Roic

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Sensus Healthcare, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →